

# **Immunoviva Investor Presentation**

Jefferies Virtual London Healthcare Conference

November 18<sup>th</sup>, 2020

# Forward Looking Statements

IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”).

The Information has been prepared and issued by the Company solely for use at the presentation held by the Company in relation to the Company’s operations and position. The Information has not been independently verified and will not be updated. Unless otherwise stated, and any market data used in the Information is not attributed to a specific source, are estimates of the Company, and have not been independently verified. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.

THE INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND BACKGROUND.

The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities issued by the Company.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

# Presenter

---



**Patrik Dahlen**  
CEO of Immunovia

# Immunovia Key Investment Highlights

*First Mover Advantage with IMMray™ PanCan-d*

## **IMMray™ Platform Technology**

Proprietary Blood-Based Biomarker Platform

## **Significant Unmet Medical Need for Early Detection of Pancreatic Cancer**

Initial Addressable Market Size (EU/US)  
~\$4.4 Bn (USD)

## **First-To-Market Opportunity for IMMray™ PanCan-d**


Expected Sales Starting In Q1 2021  
Subsequent Testing in Q2 2021

## **Leverageable Platform: IMMray™**

Pipeline Indications: Lung Cancer & Rheumatoid Arthritis

# Company Overview

Listed on NASDAQ Stockholm (ticker IMMNOV)




LUNDS UNIVERSITET



World renowned Translational  
Cancer Center

IP-rights for IMMray™ platform  
tests transferred to Immunovia AB.




# Differentiated Technology Platform: IMMray™

## Patient Sample Testing In The Lab

### IMMray™ Dx LABORATORY ANALYSIS

Day 1-2


Day 3



# Significant Unmet Medical Need

## *Early Detection of Pancreatic Cancer*

~50% ————— Five Year Survival —————> <5%



STAGE I  
Resectable

STAGE II  
Resectable / Borderline resectable

STAGE III  
Unresectable

STAGE IV  
Unresectable

Early Diagnosis In Pancreatic Cancer Is The  
Only Hope

Today >80% Late Diagnosis



4.6 Months Median Survival  
Someone Diagnosed With Pancreatic  
Cancer In Europe

# IMMray™ PanCan-d Targeting Three High-Risk Groups

## Hereditary Familial



- Familial autosomal  $\geq 2$  close fam members
- Familiar non-autosomal  $\geq 3$  close fam members
- BRCA1/2 Hereditary
- FAMMM p16, CDKN2A
- Peutz Jeghers
- Lynch Syndrome
- Hereditary pancreatitis
- 2-132 risk of developing pancreatic cancer

## Early/ Concerning symptoms




- Depression
- Indigestion/Nausea
- Jaundice
- Mid back pain
- Upper abdominal pain
- Pain on eating
- Fatigue
- Unexplained weight loss
- Diabetes

## NOD



- New onset diabetes type II after 50 years of age
- 8-10 times increased risk of developing pancreatic cancer 1-3 year after diagnosis


# IMMray™ PanCan-d Targets Initial Addressable Market of ~\$4.4bn (USD) in US/EU



Targeting A Long-Term 30% Market Share

# IMMray™ PanCan-d Commercial Test Model Study

*Confirmed Results from Optimization Study with Accuracies ~95% for Diagnosing Pancreatic Cancer vs All Controls*



immunovia

Immunovia's IMMray™ PanCan-d Webinar Series  
September 2, 2020

**Webinar No. 2: Commercial Test Model Study  
& Update on Launch Activities**

Linda Mellby, PhD, Laura Chirica, PhD,  
Thomas King, MD, PhD, Immunovia

2020-09-02 1

immunovia

Multicenter case-control study  
8 US and EU sites

- 315 PDAC, stage I-IV
- 310 Healthy controls
- 488 Symptomatic controls

Total: 1113 serum samples

**UIC** **Region Halland** **Beth Israel Lahey Health** **Beth Israel Deaconess Medical Center** **UPMC** **REGION KRONBERG** **NYU Langone Health** **Hospital Universitario Ramón y Cajal**

2020-09-02 11

immunovia

Controls prospectively collected in secondary care centers and gastrointestinal units

Clinically relevant controls		
Intended clinical use	Non-PDAC controls with symptoms suggestive of PDAC	Various benign pancreatic and biliary diseases

Patient samples were fully randomized based on clinical parameters over slides and days of analysis.

2020-09-02 12

immunovia

IMMray™ PanCan-d Test Model



8-plex biomarker signature + CA19-9

Pancreatic Cancer  
PDAC Stage I-IV  
n=315

VS

Controls  
Symptomatic and Healthy Controls  
n=798

2020-09-02 13



# IMMray™ PanCan-d Clinical Verification Study

*IMMray™ PanCan-d test for PDAC vs. non-PDAC controls (including healthy and symptomatic controls)*



Multi center case-control study covering 519 patients  
Serum samples from 9 different US and EU based sites/cohorts

- 81 PDAC Stage I/II
- 114 PDAC Stage III/IV
- 212 healthy
- 112 symptomatic controls




## Study Design

New independent samples cohorts run according to product configuration, locked IMMray™ PanCan-d signature and model cut off. Using verified SW, locked production processes, and QC methods.




## Classification performance IMMray™ PanCan-d

### PDAC vs. Healthy controls



### PDAC vs. All Controls



IMMray™ PanCan-d in combination with CA 19-9 leads to accuracy of 94% in differentiating early stage I/II PDAC patients from healthy controls

- specificity of 99%
- sensitivity of 78%
- NPV of 0.993

Early Stages I/II PDAC were differentiated from all the controls (symptomatic and healthy controls) with an accuracy of 91%

- specificity of 93%
- sensitivity of 78%
- NPV of 0.993


Sample collection and preparation for blind validation study is ongoing, however recruitments affected by Corona infections on the rise in sample collecting countries.



# The Road to Sales Start Q1 2021


*Subsequent Testing in Q2 2021*

***We Are Here***



**Sales Start  
Q1 2021 with  
Subsequent  
Testing Q2 2021**

# IMMray™ PanCan-d Road to Market Timeline



# IMMray™ PanCan-d Launch Regions by Priority

1<sup>st</sup> Wave US Commercialization

2<sup>nd</sup> Wave Europe Commercialization

Sweden/Nordic

UK


Spain / Italy

DACH

Benelux

France


Canada



Countries with prospective site centers, PanFAM, PanSYM, PanDIA, familial pancreatic screening programs, diagnostic/GI centers and private health systems

# The Path to Market

## Main programs



# World's Largest Key Opinion Leader Network

(US & Europe)

Over 30 KOLs worldwide, including:

## North America

### Montreal, CA

Research Institute of the  
McGill University Health  
Center (RI-MUHC)

### Massachusetts

Massachusetts General  
Hospital

University of  
Massachusetts  
Beth Israel Deaconess  
Medical Center

### Connecticut

Yale University

### New York

Columbia University  
Mount Sinai  
NYU School of Medicine

### Pennsylvania

The Trustees of the  
University of PENN  
University of Pittsburg  
Medical Center

### Illinois

University of Chicago

### Oregon

OHSU Knight Cancer  
Institutet Portland

### California

Stanford  
UCLA Health Medical



## Europe

### SWEDEN

Umeå University Hospital  
Karolinska Institute  
Linköping University  
Hospital  
Sahlgrenska University  
Hospital

### UNITED KINGDOM

#### London

University College  
London Hospital

#### Liverpool

University of Liverpool



### SPAIN

Clínica Universidad de  
Navarra (CUN)  
University Hospital -  
Santiago De Compostela  
Ramon y Cajal Institute  
for Health Research  
(IRYCIS)  
Catalan Institute of  
Oncology (ICO  
Hospitalet)  
Bellvitge Biomedical  
Research Institute

# Global Collaborations with Pancreatic Cancer Patient Organizations

## North America

### Canada

Pancreatic Cancer Canada

### USA

Lustgarten Foundation

The Pancreatic Cancer Action Network (PanCAN)

The World Pancreatic Cancer Coalition

The Ron Foley Foundation

The Griffith Family Foundation

The MA Pancreatic Cancer Alliance

The Marino/Connolly Foundation

Purple Iris Foundation

Kenner Family Research Fund

FORCE (Facing Our Risk of Cancer Empowered)

Families Fighting Pancreatic Cancer

## Europe

### SWEDEN

Palema

Nätverket mot cancer

### NORWAY

Pancreaskreft Nettverk

### DENMARK

Pancreasnetværket

### GERMANY

TEB e. V. Selbsthilfe

AdP, der Arbeitskreis der Pankreatektomierten e. V.

### U.K.

Pancreatic Cancer Action UK

PCUK - Pancreatic Cancer UK

Cancer Research UK (CRUK)

Pancreatic Cancer Research Fund (PCRF)

MacMillan Cancer Support

### SPAIN

ACANPAN


GEPAC

### JAPAN

PanCAN Japan


# Pipeline Studies: Lung Cancer & Rheumatoid Arthritis

## Immunovia's Focus Remains on Getting IMMray™ PanCan-d to Market



# IMMray™ PanCan-d US Sales Start Q1 2021

*Immunovia's vision is to dominate the pancreatic cancer diagnostics market*



Thank you!

Julie Silber  
Director of Investor Relations  
Immunovia AB  
Mobile: +46(0)79 3486277  
[julie.silber@immunovia.com](mailto:julie.silber@immunovia.com)

[www.immunovia.com](http://www.immunovia.com)